 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...193194195196197198199200201202203...235236» |
- || veliparib (ABT-888) / AbbVie
Trial primary completion date, Combination therapy, Metastases: ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov) - Feb 14, 2017
P1/2, N=79, Recruiting, Sponsor: Georgetown University
Trial primary completion date: Dec 2016 --> Dec 2017
- Enrollment change, Trial termination, Trial primary completion date, Metastases: FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer (clinicaltrials.gov) - Feb 14, 2017
P2, N=9, Terminated, Sponsor: UNC Lineberger Comprehensive Cancer Center
N=45 --> 9 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2014 --> Aug 2016; Results unlikely to impact treatment patterns. Time to complete not justified.
- || Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Enrollment change, Trial primary completion date, Combination therapy: A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors (clinicaltrials.gov) - Feb 13, 2017
P1, N=291, Recruiting, Sponsor: Hoffmann-La Roche
Time to complete not justified. N=60 --> 291 | Trial primary completion date: Nov 2018 --> May 2019
- | Bavencio (avelumab) / EMD Serono
New P2 trial, Combination therapy, Metastases: Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004 (clinicaltrials.gov) - Feb 13, 2017
P2, N=81, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- Avastin (bevacizumab) / Roche
Enrollment closed, Trial primary completion date, Metastases: Study of Vitamin D in Untreated Metastatic Colorectal Cancer (clinicaltrials.gov) - Feb 11, 2017
P2, N=120, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
N=60 --> 291 | Trial primary completion date: Nov 2018 --> May 2019 Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2016 --> Jul 2017
- | leucovorin calcium / Generic mfg., Avastin (bevacizumab) / Roche, irinotecan / Generic mfg.
Biomarker, Journal: Feasibility of novel PPP1R15A and proposed ANXA11 single nucleotide polymorphisms as predictive markers for bevacizumab regimen in metastatic colorectal cancer. (Pubmed Central) - Feb 10, 2017
Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2016 --> Jul 2017 ANXA11 rs1049550 and PPP1R15A rs557806 may improve the identification of mCRC patients sensitive to bevacizumab regimens, and further validation is required in large cohorts.
- Enrollment closed, Enrollment change, Metastases: Phase 2 Evaluation of Multi-modality Algorithm for Non-metastatic Adenocarcinoma of Pancreas or Ampulla (clinicaltrials.gov) - Feb 10, 2017
P2, N=10, Active, not recruiting, Sponsor: Essentia Health
ANXA11 rs1049550 and PPP1R15A rs557806 may improve the identification of mCRC patients sensitive to bevacizumab regimens, and further validation is required in large cohorts. Recruiting --> Active, not recruiting | N=37 --> 10
- || veliparib (ABT-888) / AbbVie
Trial primary completion date, Metastases: Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer (clinicaltrials.gov) - Feb 7, 2017
P2, N=120, Active, not recruiting, Sponsor: AbbVie
Recruiting --> Active, not recruiting | N=37 --> 10 Trial primary completion date: Jan 2017 --> May 2017
- ||| Graspa (eryaspase) / PHAXIAM Therap
Enrollment closed, Enrollment change, Metastases: Efficacy and Safety of L-asparaginase Encapsulated in RBC Combined With Gemcitabine or FOLFOX in 2nd Line for Progressive Metastatic Pancreatic Carcinoma (clinicaltrials.gov) - Feb 7, 2017
P2, N=141, Active, not recruiting, Sponsor: ERYtech Pharma
Trial primary completion date: Jan 2017 --> May 2017 Recruiting --> Active, not recruiting | N=90 --> 141
- |||| namilumab (IZN-101) / Amgen, Izana Biosci, Roivant
Combination therapy: NEXUS: Dose Finding Study of Namilumab in Combination With Methotrexate in Participants With Moderate to Severe Rheumatoid Arthritis (RA) (clinicaltrials.gov) - Feb 7, 2017
P2, N=108, Completed, Sponsor: Takeda
Recruiting --> Active, not recruiting | N=90 --> 141 Active, not recruiting --> Completed | Trial primary completion date: May 2017 --> Nov 2016
- ||||| Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
New P2 trial, Metastases: AIO-NIFE-trial: Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer (clinicaltrials.gov) - Feb 7, 2017
P2, N=92, Not yet recruiting, Sponsor: AIO-Studien-gGmbH
- | Vectibix (panitumumab) / Amgen
Trial completion: Evaluating Panitumumab (ABX-EGF) in Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Feb 6, 2017
P2, N=43, Completed, Sponsor: Amgen
Active, not recruiting --> Completed | Trial primary completion date: May 2017 --> Nov 2016 Active, not recruiting --> Completed
- ||| Vectibix (panitumumab) / Amgen
New trial, Real-world evidence: Validation of a New Prognostic Score for Adult Patients With RAS Wild-type mCRC Treated With Vectibix (clinicaltrials.gov) - Feb 6, 2017
P=N/A, N=1240, Recruiting, Sponsor: iOMEDICO AG
- ||||| Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
New P2 trial: NALIRICC: Nal-IRI and 5-FU Compared to 5-FU in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated With Gemcitabine-based Therapies (clinicaltrials.gov) - Feb 6, 2017
P2, N=100, Not yet recruiting, Sponsor: AIO-Studien-gGmbH
- ||||| Zaltrap (ziv-aflibercept IV) / Sanofi
New P2 trial: mFOLFOX6 vs. mFOLFOX6 + Aflibercept as Neoadjuvant Treatment in MRI-defined T3-rectal Cancer (clinicaltrials.gov) - Feb 6, 2017
P2, N=209, Not yet recruiting, Sponsor: AIO-Studien-gGmbH
- ||| Zaltrap (ziv-aflibercept IV) / Sanofi
Enrollment closed, Trial primary completion date, Metastases: RIA: Induction FOLFOX With or Without Aflibercept Followed by Chemoradiation in High Risk Locally Advanced Rectal Cancer (clinicaltrials.gov) - Feb 3, 2017
P2, N=180, Active, not recruiting, Sponsor: Grupo Espanol Multidisciplinario del Cancer Digestivo
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2017 --> Sep 2017
- Trial completion, Enrollment change, Metastases: NabucCO: Phase I/II Study to Evaluate Nab-paclitaxel in Substitution of CPT11 or Oxaliplatin in FOLFIRINOX Schedule as First Line Treatment in Metastatic Pancreatic Cancer (clinicaltrials.gov) - Feb 3, 2017
P1/2, N=148, Completed, Sponsor: Gruppo Oncologico Italiano di Ricerca Clinica
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2017 --> Sep 2017 Recruiting --> Completed | N=114 --> 148
- New P2 trial, Metastases: FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas (clinicaltrials.gov) - Feb 2, 2017
P2, N=28, Recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
- Trial primary completion date: Fosaprepitant Dimeglumine in Preventing Nausea and Vomiting in Patients With Gastrointestinal Cancer Receiving Combination Chemotherapy (clinicaltrials.gov) - Feb 2, 2017
P=N/A, N=42, Active, not recruiting, Sponsor: Philip Philip
Recruiting --> Completed | N=114 --> 148 Trial primary completion date: Dec 2016 --> Apr 2017
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., sorafenib / Generic mfg.
Trial primary completion date, Combination therapy, Metastases: Sorafenib + mFOLFOX for Hepatocellular Carcinoma (clinicaltrials.gov) - Feb 2, 2017
P2, N=40, Recruiting, Sponsor: Massachusetts General Hospital
Trial primary completion date: Dec 2016 --> Apr 2017 Trial primary completion date: Dec 2015 --> May 2017
- oxaliplatin / Generic mfg., irinotecan / Generic mfg.
Trial primary completion date, Surgery, Post-surgery: A Pilot Study of Pre- and Post-surgery Chemotherapy With mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma (clinicaltrials.gov) - Feb 1, 2017
P2, N=21, Active, not recruiting, Sponsor: NorthShore University HealthSystem
Trial primary completion date: Dec 2015 --> May 2017 Trial primary completion date: Jul 2016 --> Mar 2017
- Trial primary completion date, Combination therapy, Metastases: Ph 2 Trial of Vitamin C & G-FLIP (Low Doses Gemcitabine, 5FU, Leucovorin, Irinotecan, Oxaliplatin) for Pancreatic Cancer (clinicaltrials.gov) - Feb 1, 2017
P2, N=30, Recruiting, Sponsor: Bruckner Oncology
Trial primary completion date: Jul 2016 --> Mar 2017 Trial primary completion date: Jul 2016 --> Apr 2017
- Enrollment closed, Enrollment change, Metastases: Neoadjuvant FOLFIRINOX Regimen in Patients With Non-metastatic Pancrease Cancer (clinicaltrials.gov) - Jan 31, 2017
P=N/A, N=30, Active, not recruiting, Sponsor: Baylor Research Institute
Trial primary completion date: Jul 2016 --> Apr 2017 Recruiting --> Active, not recruiting | N=100 --> 30
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Trial primary completion date, Metastases: BrUOG 292: FOLFOX-A For Metastatic Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial (clinicaltrials.gov) - Jan 31, 2017
P2, N=50, Recruiting, Sponsor: howard safran
Recruiting --> Active, not recruiting | N=100 --> 30 Trial primary completion date: Sep 2016 --> Sep 2017
- ||| vanucizumab (RG7221) / Roche, Avastin (bevacizumab) / Roche
Enrollment closed, Trial primary completion date, Metastases: McCAVE: A Study Comparing the Efficacy and Safety of Vanucizumab and FOLFOX With Bevacizumab and FOLFOX in Participants With Untreated Metastatic Colorectal Cancer (clinicaltrials.gov) - Jan 31, 2017
P2, N=200, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Sep 2016 --> Sep 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2017 --> Jul 2016
- Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Trial completion, Enrollment change, Trial primary completion date, Metastases: DOUBLIRI: A Dose Escalation Study of MM-398 Plus Irinotecan in Patients With Unresectable Advanced Cancer (clinicaltrials.gov) - Jan 31, 2017
P1, N=10, Completed, Sponsor: Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2017 --> Jul 2016 Recruiting --> Completed | N=36 --> 10 | Trial primary completion date: Jan 2018 --> Dec 2016
- ||| SIR-Spheres (yttrium-90 microspheres) / SIRTeX Medical
Trial completion, Trial primary completion date: SIRFLOX: FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer (clinicaltrials.gov) - Jan 30, 2017
P=N/A, N=532, Completed, Sponsor: Sirtex Medical
Recruiting --> Completed | N=36 --> 10 | Trial primary completion date: Jan 2018 --> Dec 2016 Active, not recruiting --> Completed | Trial primary completion date: Jan 2017 --> Jun 2016
- Trial primary completion date: A Phase II Study of Neoadjuvant FOLFIRINOX (clinicaltrials.gov) - Jan 30, 2017
P2, N=48, Recruiting, Sponsor: Safi Shahda
Active, not recruiting --> Completed | Trial primary completion date: Jan 2017 --> Jun 2016 Trial primary completion date: Dec 2016 --> Dec 2017
- | Avastin (bevacizumab) / Roche
Trial completion, Enrollment change, Trial primary completion date, Metastases: Genistein in Treatment of Metastatic Colorectal Cancer (clinicaltrials.gov) - Jan 30, 2017
P1/2, N=13, Completed, Sponsor: Sofya Pintova
Trial primary completion date: Dec 2016 --> Dec 2017 Recruiting --> Completed | N=24 --> 13 | Trial primary completion date: May 2018 --> Jan 2017
- New trial, Surgery: Thrombin Generation and Platelet Activation in CRS/HIPEC (clinicaltrials.gov) - Jan 30, 2017
P=N/A, N=27, Completed, Sponsor: Ziekenhuis Oost-Limburg
- | navicixizumab (OMP-305B83) / Feng Biosci
New P1 trial, IO biomarker, Metastases: A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer (clinicaltrials.gov) - Jan 30, 2017
P1b, N=30, Recruiting, Sponsor: OncoMed Pharmaceuticals, Inc.
- | Enrollment closed, Trial primary completion date: PRODIGE-24: Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus mFolfirinox to Treat Resected Pancreatic Adenocarcinoma (clinicaltrials.gov) - Jan 26, 2017
P3, N=490, Active, not recruiting, Sponsor: UNICANCER
Recruiting --> Completed | N=24 --> 13 | Trial primary completion date: May 2018 --> Jan 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2018 --> Sep 2018
- Zaltrap (ziv-aflibercept IV) / Sanofi
Enrollment change, Trial withdrawal, Metastases: Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer (clinicaltrials.gov) - Jan 26, 2017
P2, N=0, Withdrawn, Sponsor: Weill Medical College of Cornell University
Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2018 --> Sep 2018 N=30 --> 0 | Not yet recruiting --> Withdrawn
- | MB-6 / Microbio
Phase classification, Surgery: A Trial of MB-6 for Reduction of Neutropenia Induced by Chemotherapy in Patients With Stage III Colorectal Cancer. (clinicaltrials.gov) - Jan 26, 2017
P=N/A, N=184, Recruiting, Sponsor: Microbio Co Ltd
N=30 --> 0 | Not yet recruiting --> Withdrawn Phase classification: P3 --> P=N/A
- rosmantuzumab (OMP-131R10) / Mereo Biopharma
Trial primary completion date, Combination therapy, Metastases: A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10 (clinicaltrials.gov) - Jan 26, 2017
P1, N=50, Recruiting, Sponsor: OncoMed Pharmaceuticals, Inc.
Phase classification: P3 --> P=N/A Trial primary completion date: Sep 2016 --> Sep 2017
- Trial initiation date: Adjuvant Chemotherapy Based on the Adenosine Triphosphate Tumor Chemosensitivity Assay for Hepatocellular Carcinoma After Liver Transplantation (clinicaltrials.gov) - Jan 26, 2017
P2, N=300, Not yet recruiting, Sponsor: Zhejiang University
Trial primary completion date: Sep 2016 --> Sep 2017 Initiation date: Nov 2015 --> Mar 2017
- Vectibix (panitumumab) / Amgen
Enrollment open: PANIRINOX: Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer Patients (clinicaltrials.gov) - Jan 26, 2017
P2, N=209, Recruiting, Sponsor: UNICANCER
Initiation date: Nov 2015 --> Mar 2017 Not yet recruiting --> Recruiting
- || Erbitux (cetuximab) / Eli Lilly
New P2/3 trial: PARECEC: Perioperative Chemotherapy Plus Cetuximab Versus Chemotherapy Alone for High Risk Resectable Colorectal Liver Metastasis (clinicaltrials.gov) - Jan 25, 2017
P2/3, N=154, Recruiting, Sponsor: Beijing Cancer Hospital
- Erbitux (cetuximab) / Eli Lilly
Trial completion, Trial primary completion date, Metastases: Combination Chemotherapy Plus Cetuximab in Treating Patients With Liver Metastases From Colorectal Cancer (clinicaltrials.gov) - Jan 24, 2017
P2, N=73, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Not yet recruiting --> Recruiting Trial primary completion date: Mar 2008 --> Oct 2007 | Active, not recruiting --> Completed
- Avastin (bevacizumab) / Roche
Trial primary completion date, Metastases: Escalated Dose of Irinotecan in mCRC (clinicaltrials.gov) - Jan 24, 2017
P=N/A, N=320, Recruiting, Sponsor: Jaw-Yuan Wang, MD, PhD
Trial primary completion date: Mar 2008 --> Oct 2007 | Active, not recruiting --> Completed Trial primary completion date: Jun 2016 --> Dec 2017
- || Vectibix (panitumumab) / Amgen
Trial primary completion date: FOLFOXIRI With or Without Panitumumab in Metastatic Colorectal Cancer (VOLFI) (clinicaltrials.gov) - Jan 23, 2017
P2, N=93, Recruiting, Sponsor: AIO-Studien-gGmbH
Trial primary completion date: Jun 2016 --> Dec 2017 Trial primary completion date: Dec 2016 --> Jun 2017
- Removab (catumaxomab) / NeoPharm, Trion Pharma
Trial primary completion date: Catumaxomab for Treatment of Peritoneal Carcinomatosis in Patients With Gastric Adenocarcinomas (clinicaltrials.gov) - Jan 23, 2017
P2, N=42, Active, not recruiting, Sponsor: AIO-Studien-gGmbH
Trial primary completion date: Dec 2016 --> Jun 2017 Trial primary completion date: Dec 2016 --> Mar 2017
- Keytruda (pembrolizumab) / Merck (MSD)
Trial primary completion date, Metastases: HCRN GI14-186: Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer (clinicaltrials.gov) - Jan 23, 2017
P2, N=30, Active, not recruiting, Sponsor: Safi Shahda, M.D.
Trial primary completion date: Dec 2016 --> Mar 2017 Trial primary completion date: Dec 2016 --> Aug 2017
- Enrollment open, Enrollment change, Trial primary completion date, Metastases: Proton w/FOLFIRINOX-Losartan for Pancreatic Cancer (clinicaltrials.gov) - Jan 19, 2017
P2, N=50, Recruiting, Sponsor: Massachusetts General Hospital
Trial primary completion date: Dec 2016 --> Aug 2017 Active, not recruiting --> Recruiting | N=32 --> 50 | Trial primary completion date: Dec 2016 --> Dec 2018 | Active, not recruiting --> Recruiting
- Enrollment closed, Trial primary completion date: FOLFIRINOX + RT for Pancreatic Cancer (clinicaltrials.gov) - Jan 19, 2017
P2, N=50, Active, not recruiting, Sponsor: Massachusetts General Hospital
Active, not recruiting --> Recruiting | N=32 --> 50 | Trial primary completion date: Dec 2016 --> Dec 2018 | Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2016 --> Dec 2018
- futuximab/modotuximab (S95026) / Servier
Enrollment closed, Enrollment change, Combination therapy, Metastases: Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients (clinicaltrials.gov) - Jan 19, 2017
P1b/2a, N=10, Active, not recruiting, Sponsor: Symphogen A/S
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2016 --> Dec 2018 Recruiting --> Active, not recruiting | N=50 --> 10
- Trial primary completion date, Surgery: GCC 1324: Borderline Pancreas Study: FOLFIRINOX +SBRT (clinicaltrials.gov) - Jan 17, 2017
P0, N=20, Recruiting, Sponsor: University of Maryland
Recruiting --> Active, not recruiting | N=50 --> 10 Trial primary completion date: Dec 2016 --> Dec 2017
- Trial primary completion date: Colon Neoadjuvant FOLFOXIRI Study (clinicaltrials.gov) - Jan 13, 2017
P2, N=40, Recruiting, Sponsor: Chinese University of Hong Kong
Trial primary completion date: Dec 2016 --> Dec 2017 Trial primary completion date: Dec 2016 --> Dec 2017
- Trial primary completion date, Surgery, Metastases: Chemotherapy Followed by Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Head And Neck Cancer (clinicaltrials.gov) - Jan 13, 2017
P2, N=30, Active, not recruiting, Sponsor: City of Hope Medical Center
Trial primary completion date: Dec 2016 --> Dec 2017 Trial primary completion date: Dec 2016 --> Jan 2018
- |||||||||| Decadron (dexamethasone) / Merck (MSD), Oncaspar liquid (pegaspargase) / Servier
New P3 trial: DFCI 16-001: Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents (clinicaltrials.gov) - Jan 13, 2017
P3, N=400, Not yet recruiting, Sponsor: Dana-Farber Cancer Institute